Literature DB >> 10543749

Decreased antipyrine clearance following endotoxin administration: in vivo evidence of the role of nitric oxide.

K Kitaichi1, L Wang, K Takagi, M Iwase, E Shibata, M Nadai, T Hasegawa.   

Abstract

Klebsiella pneumoniae endotoxin has been found to decrease hepatic P450-mediated drug-metabolizing enzyme activity in a time-dependent manner. In this study, we investigated the role of nitric oxide (NO) in the decrease in hepatic drug-metabolizing enzyme activity caused by endotoxin in vivo. We measured in vivo pharmacokinetic parameters of antipyrine in rats treated with endotoxin and/or a selective inhibitor of inducible NO synthase (iNOS), S-methylisothiourea. Intraperitoneal injection of endotoxin (1 mg/kg of body weight) dramatically decreased the systemic clearance of antipyrine, reflecting reduced hepatic drug-metabolizing enzyme activity, and significantly increased the level of nitrite and nitrate (NOx) in the plasma. S-Methylisothiourea (10 mg/kg) reversed this decreasing antipyrine clearance and reduced the level of NOx in plasma. Repeated injections of an NO donor, (+/-)-(E)-4-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexenamide (FK-409; 10 mg/kg), at a dose which maintained plasma NOx at the same levels as those caused by endotoxin injection, also decreased the systemic clearance of antipyrine. These findings suggest that the overproduction of NO observed in this animal model is at least partially responsible for the significant reduction in the hepatic drug-metabolizing enzyme activity that may happen in a gram-negative bacterial infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10543749      PMCID: PMC89545     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

Review 1.  Nitric oxide: physiology, pathophysiology, and pharmacology.

Authors:  S Moncada; R M Palmer; E A Higgs
Journal:  Pharmacol Rev       Date:  1991-06       Impact factor: 25.468

2.  Structure of the polysaccharide moiety of the Klebsiella O3 lipopolysaccharide isolated from culture supernatant of decapsulated mutant (Klebsiella O3:K1-).

Authors:  T Hasegawa; M Ohta; I Nakashima; N Kato; K Morikawa; T Harada; T Okuyama
Journal:  Chem Pharm Bull (Tokyo)       Date:  1985-01       Impact factor: 1.645

3.  Antipyrine clearance in pneumonia.

Authors:  J Sonne; M Døssing; S Loft; P B Andreasen
Journal:  Clin Pharmacol Ther       Date:  1985-06       Impact factor: 6.875

4.  A one-sample method for antipyrine clearance determination in rats.

Authors:  H Pilsgaard; H E Poulsen
Journal:  Pharmacology       Date:  1984       Impact factor: 2.547

5.  A pharmacokinetic analysis program (multi) for microcomputer.

Authors:  K Yamaoka; Y Tanigawara; T Nakagawa; T Uno
Journal:  J Pharmacobiodyn       Date:  1981-11

6.  Regulation of cytochrome P450IIC12 expression by interleukin-1 alpha, interleukin-6, and dexamethasone.

Authors:  K Wright; E T Morgan
Journal:  Mol Pharmacol       Date:  1991-04       Impact factor: 4.436

7.  The Klebsiella O3 lipopolysaccharide isolated from culture fluid: structure of the polysaccharide moiety.

Authors:  T Hasegawa; M Ohta; M Mori; I Nakashima; N Kato
Journal:  Microbiol Immunol       Date:  1983       Impact factor: 1.955

8.  Deficient metabolism of debrisoquine and sparteine.

Authors:  T Inaba; S V Otton; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1980-04       Impact factor: 6.875

9.  Role of interleukin-1 in the depression of liver drug metabolism by endotoxin.

Authors:  P Ghezzi; B Saccardo; P Villa; V Rossi; M Bianchi; C A Dinarello
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

10.  Further Studies of the polysaccharide of Klebsiella pneumoniae possessing strong adjuvanticity. I. Production of the adjuvant polysaccharide by noncapsulated mutant.

Authors:  M Ohta; M Mori; T Hasegawa; F Nagase; I Nakashima; S Naito; N Kato
Journal:  Microbiol Immunol       Date:  1981       Impact factor: 1.955

View more
  5 in total

Review 1.  Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin.

Authors:  J F Westphal
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

2.  Association of serum NO( x ) level with clustering of metabolic syndrome components in middle-aged and elderly general populations in Japan.

Authors:  Jun Ueyama; Takaaki Kondo; Ryota Imai; Akiko Kimata; Kanami Yamamoto; Koji Suzuki; Takashi Inoue; Yoshinori Ito; Ken-Ichi Miyamoto; Takaaki Hasegawa; Nobuyuki Hamajima
Journal:  Environ Health Prev Med       Date:  2007-12-11       Impact factor: 3.674

3.  Regulation of cytochrome P450 enzyme activity and expression by nitric oxide in the context of inflammatory disease.

Authors:  Edward T Morgan; Cene Skubic; Choon-Myung Lee; Kaja Blagotinšek Cokan; Damjana Rozman
Journal:  Drug Metab Rev       Date:  2020-09-08       Impact factor: 4.518

4.  Shiga-like toxin II derived from Escherichia coli O157:H7 modifies renal handling of levofloxacin in rats.

Authors:  Ying Lan Zhao; Xiao Bo Cen; Masafumi Ito; Keiko Yokoyama; Kenji Takagi; Kiyoyuki Kitaichi; Masayuki Nadai; Michio Ohta; Kenzo Takagi; Takaaki Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

5.  Effect of endotoxin on P-glycoprotein-mediated biliary and renal excretion of rhodamine-123 in rats.

Authors:  H Ando; Y Nishio; K Ito; A Nakao; L Wang; Y L Zhao; K Kitaichi; K Takagi; T Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.